Literature DB >> 12857063

Results of radiation therapy for uterine cervical cancer using high dose rate remote after loading system.

Yoshihiro Ogawa1, Kenji Nemoto, Yoshihisa Kakuto, Hisanori Ariga, Haruo Matsushita, Ken Takeda, Chiaki Takahashi, Britton Gallardo, Keith Richard, Yoshihiro Takai, Shogo Yamada.   

Abstract

In Japan, radiotherapy with high dose rate remote after loading system (HDR-RALS) for intracavitary brachytherapy is the standard treatment for more than 30 years. This report showed the usefulness of HDR-RALS for uterine cervical cancer. From 1980 through 1999, 442 patients with uterine cervical cancers (stage I: 66, stage II: 161, stage III: 165, stage IV: 50) were treated. Radiotherapy was performed both external teletherapy and HDR-RALS. Overall survival rate at 5 years was 60.2%. The 5-year actuarial incidence of all complications was 16.4%. The 5-year actuarial incidence of all complications in cases treated with the sum doses of whole pelvic irradiation (without central shield) and RALS up to 49 Gy, 50 to 59 Gy or larger doses were 7.5%, 11.0% and 25.2%, respectively. Radiation therapy using HDR-RALS was very effective. While the dose of whole pelvic irradiation was increased, the actuarial incidence of all complications was increased.

Entities:  

Mesh:

Year:  2003        PMID: 12857063     DOI: 10.1620/tjem.199.229

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  2 in total

Review 1.  American Brachytherapy Task Group Report: A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer.

Authors:  Jyoti Mayadev; Akila Viswanathan; Yu Liu; Chin-Shang Li; Kevin Albuquerque; Antonio L Damato; Sushil Beriwal; Beth Erickson
Journal:  Brachytherapy       Date:  2017 Jan - Feb       Impact factor: 2.362

2.  Assessment of the anatomical position of point B and the relationship between point B dose and the dose delivered to pelvic lymph nodes in CT-based high-dose-rate brachytherapy for uterine cervical cancer.

Authors:  Hideaki Matsukawa; Tomonari Sasaki; Ryota Hirayama; Taka-Aki Hirose; Jun-Ichi Fukunaga
Journal:  J Contemp Brachytherapy       Date:  2019-04-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.